 

## Amendment No. 014830.1

**Amendment of Agreement Number 014830, entitled “Ximbio Materials Licence and Revenue Sharing Agreement” dated 17th December 2020 (the “Agreement”)**

Contracting parties:

## Cancer Research Technology Limited

a company registered in England with company number 1626049, with its registered seat at 2 Redman Place, London,

E201JQ, United Kingdom

(originally in the Agreement referred to as “Ximbio” and hereinafter referred to as “**CancerTools.org**”) and

**Ústav molekulární genetiky AV Čr, v. v. i.** (in English reffered to as “Institute of Molecular Genetics of the Czech Academy of Sciences

with its registered seat at Vídeňská 1083, 142 20 Prague 4, Czech Republic, Reg. No.: 68378050, VAT ID: CZ68378050 (hereinafter referred to as “**Institute**”)

The purpose of this Amendment 014830.1 is to update reference to Ximbio’s sister brand, CancerTools.org, and to amend the Agreement as set out below. “CancerTools.org” is the new trading name of CRT’s diagnostic tools and reagents business. CancerTools.org manages the collection, production and dissemination of life science laboratory research tools, reagents and materials around the world.

This Amendment 014830.1 shall take effect from the date of its publishing in the Register of Contracts according to Act. No. 340/2015 Coll., described in Clause 5.7 of the Agreement, as notified in writing by the Institute and hereby amends the Agreement as follows:

1. Throughout the Agreement, all references to “Ximbio” are deleted and replaced with “CancerTools.org”.
2. The following new definitions are added to Clause 1.1 of the Agreement as follows:

|  |  |
| --- | --- |
| **“Commercial Customer”** | means any Customer that is not a Non-Commercial Customer. |
| **“Customer”** | means any user of Research Tools provided under this Agreement, whether for commercial or non-commercial use. |
| **“Goods”** | means the tangible Research Tools provided by CancerTools.org to its Customers under this Agreement, including but not limited to aliquots of cell line or a well plate of tool compound. |
| **“Goods Revenue”** | means the actual gross sales amount received for the sale of Goods by CancerTools.org, less any sales and/or use taxes actually paid, import and/or export duties actually paid, outbound transportation paid, allowed, or received, any trade discounts, and amounts allowed or credited due to returns. |

|  |  |
| --- | --- |
| **“Licensing Revenue”** | means the actual gross sales amount received by CancerTools.org from its Sub-Licensees for licence fees, royalties and other monetary consideration during the course of commercialisation of the Research Tools , excluding Goods Revenue, less any sales and/or use taxes actually paid, import and/or export duties actually paid, outbound transportation paid, allowed, or received, any trade discounts, and amounts allowed or credited due to returns. |
| **“Non-Commercial Customer”** | means any Customer that is an academic or teaching institute, charity or other not-for- profit organisation. |
| **“Sub-Licensee”** | means any Commercial Customer that CancerTools.org enters into a sub-licence agreement with pertaining to the Research Tools in the Field of Use. |

1. The definition of “Field of Use” in Clause 1.1 of the Agreement is deleted and replaced with:

**“Field of Use”**

means i) research use only (“RUO”) and/or ii) in vitro diagnostic use (“IVD”) as specified in Appendix A; by commercial and/or non-commercial organisations, and excluding therapeutic use or any in vivo use in human subjects.

1. The definition of “Ximbio Revenue” in Clause 1.1 of the Agreement is deleted and replaced with:

**“Revenue”**

means both Goods Revenue and Licensing Revenue.

1. Appendix A of the Agreement is deleted and replaced with the Appendix A attached to this Amendment

014830.1. Appendix A attached to this Amendment 014830.1 shows the complete list of Research Reagents now under the Agreement.

1. Table 1 of Appendix A shall list all of the Research Reagents under the Agreement that have been sub-licensed to third parties prior to the date of this Amendment 014830.1. Table 2 of Appendix A shall list all of the Research Reagents under the Agreement that have not been sub-licensed to third parties prior to the date of this Amendment 014830.1.
2. Clause 3.1 of the Agreement shall be amended as follows (additions shown as double underlined (“ ”) and deletions shown as strike-through (“ ”):
   1. The Institution hereby grants to CancerTools.org, worldwide, non-exclusive licences in the Field of Use in respect of the Research Reagents listed in Appendix A and associated Data, to:

With regards to RUO:

* + 1. make, have made, use, store, have stored, offer for sale, sell, offer to supply, supply and/or otherwise commercialise Research Reagents howsoever; and
    2. to grant non-exclusive sub-licences to Non-Commercial Customers to make, use, sell and/or supply Research Reagents.

For clarity, the right in Clause 3.1(b) does not include the right for such Non-Commercial Customers to grant any licences to anyone else to make, sell and/or supply the Research Reagents.

* + 1. to grant non-exclusive sub-licences to Commercial Customers to make and use Research Reagents.

For clarity, the right in Clause 3.1(c) does not include the right for such Commercial Customers to sell or supply Research Reagents, or to grant any licences to anyone else to make, sell and/or supply the Research Reagents. This does not prohibit contract research organisations from making and using Research Reagents in their client research projects on behalf of a Customer.

With regards to IVD ONLY:

* + 1. to grant non-exclusive sub-licences to Commercial Customers to make, use, sell and supply Research Reagents.

For clarity, the right in Clause 3.1(d) does not include the right for such Commercial Customers to grant any licences to anyone else to make, sell and/or supply the Research Reagents.

1. A new Clause 3.3 is added to the Agreement as follows:

**3.3.** Notwithstanding anything to the contrary in this Agreement, if a Research Tool is either a small molecule tool compound, protein, probe or other type of research tool that CancerTools.org, before or after execution of this Agreement, determines (at its sole discretion) is not commercially practicable to make or have made (“**Special Research Tool**”), CancerTools.org shall use reasonable endeavours to notify the Institution accordingly and shall not be under any obligation to commercialise such Special Research Tool under this Agreement. If the Institution wishes CancerTools.org to commercialise such Special Research Tool after execution of this Agreement and/or a Customer requests such Special Research Tool from CancerTools.org, at CancerTools.org’s sole discretion the Parties shall in good faith negotiate a separate agreement for the supply and subsequent commercialisation of such Special Research Tool on mutually agreed terms. Special Research Tools will be identified in Appendix A.

1. Clause 4.1 of the Agreement is deleted and replaced with the following:

**4.1**

In consideration of the rights granted under this Agreement, CancerTools.org shall pay to the Institution:

i.

Twenty five percent (25%) of Goods Revenue; and

ii.

Sixty percent (60%) of Licensing Revenue.

Where any Revenue is received by CancerTools.org as part of the consideration of the grant of rights which include

rights other than those arising under the Research Reagents, CancerTools.org shall apportion the consideration as between, on the one hand, the rights granted under any of the Research Reagents and on the other, any other rights granted in such manner as is fair and reasonable.

The new payment terms as outlined above in Clause 4.1 of this Amendment 014830.1, shall take effect from the date of this Amendment 014830.1. For clarity the next Accounting Period shall be 01 April 2022 to 31 March 2023 and the related electronic revenue sharing report will be due on 30 May 2023 and the updated terms of Clause 4.1 shall apply to the entire Accounting Period, even though some rights were granted prior to the effective date of this Amendment.

1. With respect of CancerTools.org, any notices and correspondence relating to the Agreement shall be sent to Cancer Research Technology Ltd at the address set out above and/or sent by electronic mail to [Licensing@cancertools.org,](mailto:Licensing@cancertools.org) marked for the attention of the Global Head, CancerTools.org.
2. Under the Agreement the Parties agree to update Appendix A to include new Research Reagents:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Name** | **Description** | **Reference** | **Inventor** | **CancerTools Reference (Tech ID)** |
| α-tubulin (N- terminal domain)  IgM (TU-05)  Monoclonal antibody | Antibodies to tubulin associated proteins TU-05 | PMID: 2459085 | xxx; Laboratory of Biology of Cytoskeleton | Xbio/IMG/TU-05 |
| α-tubulin (N- terminal domain)  IgM (TU-09)  Monoclonal antibody | Antibodies to tubulin associated proteins TU-09 | PMID: 2459085 | xxx; Laboratory of Biology of Cytoskeleton | Xbio/IMG/TU-09 |
| anti-GCP2 tubulin associated protein IgG2b  (04) Monoclonal antibody | Antibodies to tubulin- associated proteins GCP2- 04 | Unpublished | xxx; Laboratory of Biology of Cytoskeleton | Xbio/IMG/P2-04 |
| anti-GCP2 tubulin associated protein IgG1 (05) | Antibodies to tubulin- associated | Unpublished | xxx; Laboratory of Biology of Cytoskeleton | Xbio/IMG/P2-05 |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Monoclonal antibody | proteins GCP2- 05 |  |  |  |
| anti-MAP2ab IgG1 (MT-07)  Monoclonal antibody | Antibodies to tubulin- associated proteins MT-07 | Unpublished | xxx; Laboratory of Biology of Cytoskeleton | Xbio/IMG/MT-07 |
| anti-MAP2ab IgG1 (MT-08)  Monoclonal antibody | Antibodies to tubulin- associated proteins MT-08 | Unpublished | xxx; Laboratory of Biology of Cytoskeleton | Xbio/IMG/MT-08 |
| anti- RPSA IgG1 (TPX2-01)  Monoclonal antibody | Antibodies to tubulin- associated proteins TPX2- 01 | Unpublished | xxx; Laboratory of Biology of Cytoskeleton | Xbio/IMG/TPX2-01 |
| anti- MAP2ab IgG2a (RP-01)  Monoclonal antibody | Antibodies to RPSA RP-01 | Unpublished | xxx; Laboratory of Biology of Cytoskeleton | Xbio/IMG/RP-01 |
| anti- MAP2ab IgG2a (RP-02)  Monoclonal antibody | Antibodies to RPSA RP-02 | Unpublished | xxx; Laboratory of Biology of Cytoskeleton | Xbio/IMG/RP-02 |
| anti- tripeptidyl peptidase II (TPP  II) IgG2a (TPP2-  02) Monoclonal antibody | Antibodies to tripeptidyl peptidase II (TPP II) TPP2-02 | Unpublished | xxx; Laboratory of Biology of Cytoskeleton | Xbio/IMG/TPP2-02 |
| anti- tripeptidyl peptidase II (TPP  II) IgG2a (TPP2-  03) Monoclonal antibody | Antibodies to tripeptidyl peptidase II (TPP II) TPP2-03 | Unpublished | xxx; Laboratory of Biology of Cytoskeleton | Xbio/IMG/TPP2-03 |
| anti- gamma- tubulin GCP3 IgG1 (GCP3-01)  Monoclonal antibody | Antibodies to gamma-tubulin GCP3-01 | PMID: 35159364 | xxx; Laboratory of Biology of Cytoskeleton | Xbio/IMG/GCP3-01 |
| anti- gamma- tubulin GCP3 IgM (GCP5-01) | Antibodies to gamma-tubulin GCP5-01 | Unpublished | xxx; Laboratory of Biology of Cytoskeleton | Xbio/IMG/GCP5-01 |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Monoclonal antibody |  |  |  |  |
| anti- glutathion- S-transferáza GST Ig2b (GST-  01) Monoclonal antibody | Antibodies to glutathion-S- transferáza GST-01 | Unpublished | xxx; Laboratory of Biology of Cytoskeleton | Xbio/IMG/GST-01 |
| anti- PPM1D C- terminal domain IgG1 (WIP-5)  Monoclonal antibody | Antibodies to PPM1D/Wip1 C-  terminal domain WIP-5 | PMID: 32927737 | xxx | Xbio/IMG/WIP-5 |
| anti- PPM1D C- terminal domain IgG1 (WIP-10)  Monoclonal antibody | Antibodies to PPM1D/Wip1 C-  terminal domain WIP-10 | PMID: 32927737 | xxx | Xbio/IMG/WIP-10 |
| anti-mGluR1b 1D7.F11.D10  (mono a-1b) Monoclonal antibody | Antibody to Metabotropic glutamate receptor - novel 1b variant | PMID: 25158311 | xxx | Xbio/IMG/a-1b |
| anti-SARS-COV- 2-SPIKE1  3B11/B11/A3/A8  Monoclonal antibody | Antibody to SARS-COV-2- SPIKE1 not RBD  sensitive | unpublished | xxx | Xbio/IMG/A3A8 |
| anti-SARS-COV- 2-SPIKE1  3B11/B11/A3/B6  Monoclonal antibody | Antibody to SARS-COV-2- SPIKE1 not RBD  sensitive | unpublished | xxx | Xbio/IMG/A3B6 |
| anti-SARS-COV- 2-SPIKE1  5F4/A9/G3/A1  Monoclonal antibody | Antibody to SARS-COV-2- SPIKE1 RBD  sensitive | unpublished | xxx | Xbio/IMG/G3A1 |
| anti-SARS-COV- 2-SPIKE1  5F4/A9/G3/B11  Monoclonal antibody | Antibody to SARS-COV-2- SPIKE1 RBD  sensitive | unpublished | xxx | Xbio/IMG/G3B11 |

1. Unless otherwise defined herein, all capitalised terms in this Amendment 014830.1 shall have the meaning given to such terms in the Agreement.
2. Save as outlined above, all other terms and conditions of the Agreement shall remain unamended and unaffected by this Amendment 014830.1. If there is any conflict between the terms of the Agreement and this Amendment 014830.1, the terms of this Amendment 014830.1 shall prevail.
3. Clause 9 (Governing Law and Jurisdiction) of the Agreement shall apply to this Amendment 014830.1 as if set out in this Amendment 014830.1.

# 13-May-2023

23-May-2023

London, on ………………………… Prague, on …………………………

Cancer Research Technology Ltd. Institut molekulární genetiky AV ČR, v. v. i.

……………………………..………………………… ……………………………………………………

RNDr. Petr Dráber, DrSc.

Head of Business Development director

[Ad\*b Ac-\*ba/ S$") T-a).ac/$\*) N0(b -ѷ CBJCHBCAABAA4пaх$P](https://secure.na1.echosign.com/verifier?tx=CBJCHBCAABAAy0a6iPVKvG_VpZ6-mkPGS2mXRVS7EM2F)VK1GҔV+ZхҊ(&PGSс(XRVSцEMсF [Ad\*b Ac-\*ba/ S$") T-a).ac/$\*) N0(b -ѷ CBJCHBCAABAA4пaх$P](https://secure.na1.echosign.com/verifier?tx=CBJCHBCAABAAy0a6iPVKvG_VpZ6-mkPGS2mXRVS7EM2F)VK1GҔV+ZхҊ(&PGSс(XRVSцEMсF

## Appendix A

LIST OF RESEARCH TOOLS GOVERNED BY THIS AGREEMENT

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Research Tool Type** | **Research Tool Name** | **Research Tool Description** | **Research Publications** | **Patents and/or Existing Licences** | **CancerTools Reference** | **Inventor/s Name** | **RUO and/or IVD** |
| hybridoma cell line | anti-α-tubulin (N- terminal domain) IgG1 (TU-01) hybridoma cell line |  | PMID: 16751367 |  | Xbio/IMG/TU-01 | xxx Laboratory of Biology of Cytoskeleton | RUO |
| hybridoma cell line | anti-α-tubulin (N- terminal domain) IgM (TU-03) hybridoma cell line |  | PMID: 2480356 |  | Xbio/IMG/TU-03 | xxx Laboratory of Biology of Cytoskeleton | RUO |
| hybridoma cell line | anti-α-tubulin (N- terminal domain) IgM (TU-08) hybridoma cell line |  | PMID: 10730874 |  | Xbio/IMG/TU-08 | xxx; Laboratory of Biology of Cytoskeleton | RUO |
| hybridoma cell line | anti-α-tubulin (C- terminal domain) IgM (TU-04) hybridoma cell line |  | PMID: 9157006 |  | Xbio/IMG/TU-04 | xxx Laboratory of Biology of Cytoskeleton | RUO |
| hybridoma cell line | anti-α-tubulin (C- terminal domain) IgM |  | PMID: 23851142 |  | Xbio/IMG/TU-07 | xxx | RUO |

8

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | (TU-07) hybridoma cell line |  |  |  |  | [;](mailto:pavel.draber@img.cas.cz) Laboratory of Biology of Cytoskeleton |  |
| hybridoma cell line | anti- αβ-tubulin dimer IgM (TU-18) hybridoma cell line |  | PMID: 9541471 |  | Xbio/IMG/TU-18 | xxx Laboratory of Biology of Cytoskeleton | RUO |
| hybridoma cell line | anti- γ-tubulin dimer IgG2b (TU-31)  hybridoma cell line |  | PMID: 28119396 |  | Xbio/IMG/TU-31 | xxx Laboratory of Biology of Cytoskeleton | RUO |
| hybridoma cell line | anti- γ-tubulin dimer IgG1 (TU-32)  hybridoma cell line |  | PMID: 28119396 |  | Xbio/IMG/TU-32 | xxx Laboratory of Biology of Cytoskeleton | RUO |
| hybridoma cell line | anti-GCP2 tubulin associated protein IgG1 (02) hybridoma cell line |  | PMID: 26658290 |  | Xbio/IMG/C2-02 | xxx Laboratory of Biology of Cytoskeleton | RUO |
| hybridoma cell line | anti-GCP2 tubulin associated protein IgG1 (03) hybridoma cell line |  | PMID: 26658290 |  | Xbio/IMG/P2-03 | xxx Laboratory of | RUO |

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  | Biology of Cytoskeleton |  |
| hybridoma cell line | anti-MAP2ab IgGM (MT-02) hybridoma cell line |  | PMID: 8537643 |  | Xbio/IMG/MT-02 | xxx Laboratory of Biology of Cytoskeleton | RUO |
| hybridoma cell line | anti-MAP2ab IgG2b (MT-03) hybridoma cell line |  | PMID: 10813097 |  | Xbio/IMG/MT-03 | xxx Laboratory of Biology of Cytoskeleton | RUO |
| hybridoma cell line | anti-MAP2ab IgG1  (MT-04) hybridoma cell line |  | PMID: 10813097 |  | Xbio/IMG/MT-04 | xxx Laboratory of Biology of Cytoskeleton | RUO |
| hybridoma cell line | anti-vimentin IgGM (VI-01) hybridoma cell line |  | PMID: 18379434 |  | Xbio/IMG/VI-01 | xxx Laboratory of Biology of Cytoskeleton | RUO |
| hybridoma cell line | anti-neurofilament H IgG1 (NF-04)  hybridoma cell line |  | PMID: 12802177 |  | Xbio/IMG/NF-04 | xxx Laboratory of Biology of Cytoskeleton | RUO |

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| hybridoma cell line | anti-neurofilament H IgG1 (NF-07)  hybridoma cell line |  | PMID: 12802177 |  | Xbio/IMG/NF-07 | xxx Laboratory of Biology of Cytoskeleton | RUO |
| hybridoma cell line | anti-neurofilament M IgG1 (NF-08)  hybridoma cell line |  | PMID: 12802177 |  | Xbio/IMG/NF-08 | xxx Laboratory of Biology of Cytoskeleton | RUO |
| hybridoma cell line | anti-neurofilament M IgGM (NF-10)  hybridoma cell line |  | PMID: 12802177 |  | Xbio/IMG/NF-10 | xxx Laboratory of Biology of Cytoskeleton | RUO |
| hybridoma cell line | anti-transferrin IgG1 (HTF-14) hybridoma cell line |  | PMID: 6427028 |  | Xbio/IMG/TF-14 | xxx Laboratory of Biology of Cytoskeleton | RUO |
| hybridoma cell line | anti-beta-galactosidase IgG1 (BG-02)  hybridoma cell line |  | PMID: 1500073 |  | Xbio/IMG/BG-02 | xxx Laboratory of Biology of Cytoskeleton | RUO |
| hybridoma cell line | α-tubulin (N-terminal domain)  IgM | Antibodies to tubulin associated proteins TU-05 | PMID: 2459085 |  | Xbio/IMG/TU-05 | xxx; Laboratory of | RUO |

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | (TU-05) Monoclonal antibody |  |  |  |  | Biology of Cytoskeleton |  |
| hybridoma cell line | α-tubulin (N-terminal domain)  IgM  (TU-09) Monoclonal antibody | Antibodies to tubulin associated proteins TU-09 | PMID: 2459085 |  | Xbio/IMG/TU-09 | xxx; Laboratory of Biology of Cytoskeleton | RUO |
| hybridoma cell line | anti-GCP2 tubulin associated protein IgG2b (04) Monoclonal antibody | Antibodies to tubulin- associated proteins GCP2-04 | Unpublished |  | Xbio/IMG/P2-04 | xxx; Laboratory of Biology of Cytoskeleton | RUO |
| hybridoma cell line | anti-GCP2 tubulin associated protein IgG1 (05) Monoclonal antibody | Antibodies to tubulin- associated proteins GCP2-05 | Unpublished |  | Xbio/IMG/P2-05 | xxx; Laboratory of Biology of Cytoskeleton | RUO |
| hybridoma cell line | anti-MAP2ab IgG1 (MT-07) Monoclonal antibody | Antibodies to tubulin- associated proteins MT-07 | Unpublished |  | Xbio/IMG/MT-07 | xxx; Laboratory of Biology of Cytoskeleton | RUO |
| hybridoma cell line | anti-MAP2ab IgG1 (MT-08) Monoclonal antibody | Antibodies to tubulin- associated proteins MT-08 | Unpublished |  | Xbio/IMG/MT-08 | xxx; Laboratory of Biology of Cytoskeleton | RUO |

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| hybridoma cell line | anti- RPSA IgG1 (TPX2-  01) Monoclonal antibody | Antibodies to tubulin- associated proteins TPX2-01 | Unpublished |  | Xbio/IMG/TPX2-01 | xxx Laboratory of Biology of Cytoskeleton | RUO |
| hybridoma cell line | anti- MAP2ab IgG2a (RP-01) Monoclonal antibody | Antibodies to RPSA RP-01 | Unpublished |  | Xbio/IMG/RP-01 | xxx; Laboratory of Biology of Cytoskeleton | RUO |
| hybridoma cell line | anti- MAP2ab IgG2a (RP-02) Monoclonal antibody | Antibodies to RPSA RP-02 | Unpublished |  | Xbio/IMG/RP-02 | xxx; Laboratory of Biology of Cytoskeleton | RUO |
| hybridoma cell line | anti- tripeptidyl peptidase II (TPP II) IgG2a (TPP2-02)  Monoclonal antibody | Antibodies to tripeptidyl peptidase II (TPP II) TPP2-02 | Unpublished |  | Xbio/IMG/TPP2-02 | xxx; Laboratory of Biology of Cytoskeleton | RUO |
| hybridoma cell line | anti- tripeptidyl peptidase II (TPP II) IgG2a (TPP2-03)  Monoclonal antibody | Antibodies to tripeptidyl peptidase II (TPP II) TPP2-03 | Unpublished |  | Xbio/IMG/TPP2-03 | xxx; Laboratory of Biology of Cytoskeleton | RUO |
| hybridoma cell line | anti- gamma-tubulin GCP3 IgG1 (GCP3-01)  Monoclonal antibody | Antibodies to gamma- tubulin GCP3-01 | PMID: 35159364 |  | Xbio/IMG/GCP3-01 | xxx; Laboratory of | RUO |

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  | Biology of Cytoskeleton |  |
| hybridoma cell line | anti- gamma-tubulin GCP3 IgM (GCP5-01)  Monoclonal antibody | Antibodies to gamma- tubulin GCP5-01 | Unpublished |  | Xbio/IMG/GCP5-01 | xxx; Laboratory of Biology of Cytoskeleton | RUO |
| hybridoma cell line | Anti- glutathion-S- | Antibodies to glutathion-S- | Unpublished |  | Xbio/IMG/GST-01 | xxx | RUO |
| transferáza GST Ig2b | transferáza GST-01 |  |
| (GST-01) Monoclonal | ; |
| antibody | Laboratory of |
| Biology of |
| Cytoskeleton |
| hybridoma cell line | Anti- PPM1D C-  terminal domain IgG1 (WIP-5) Monoclonal antibody | Antibodies to PPM1D/Wip1 C-terminal domain WIP-5 | PMID: 32927737 |  | Xbio/IMG/WIP-5 | xxx | RUO |
| hybridoma cell line | Anti- PPM1D C-  terminal domain IgG1 (WIP-10) Monoclonal antibody | Antibodies to PPM1D/Wip1 C-terminal domain WIP-10 | PMID: 32927737 |  | Xbio/IMG/WIP-10 | xxx | RUO |
| hybridoma cell line | Anti-mGluR1b 1D7.F11.D10 (mono a-  1b) Monoclonal antibody | Antibody to Metabotropic glutamate receptor - novel 1b variant | PMID: 25158311 |  | Xbio/IMG/a-1b | xxx | RUO |
| hybridoma cell line | anti-SARS-COV-2- SPIKE1 3B11/B11/A3/A8  Monoclonal antibody | Antibody to SARS-COV-2- SPIKE1 not RBD sensitive | unpublished |  | Xbio/IMG/A3A8 | xxx | RUO |

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| hybridoma cell line | anti-SARS-COV-2- SPIKE1 3B11/B11/A3/B6  Monoclonal antibody | Antibody to SARS-COV-2- SPIKE1 not RBD sensitive | unpublished |  | *Xbio/IMG/A3B6* | xxx | RUO |
| hybridoma cell line | anti-SARS-COV-2- SPIKE1 5F4/A9/G3/A1  Monoclonal antibody | Antibody to SARS-COV-2- SPIKE1 RBD sensitive | unpublished |  | Xbio/IMG/G3A1 | xxx | RUO |
| hybridoma cell line | anti-SARS-COV-2- SPIKE1 5F4/A9/G3/B11  Monoclonal antibody | Antibody to SARS-COV-2- SPIKE1 RBD sensitive | unpublished |  | Xbio/IMG/G3B11 | xxx | RUO |